Methods and compositions for flavoring orally-delivered products
    6.
    发明授权
    Methods and compositions for flavoring orally-delivered products 失效
    用于调味口服产品的方法和组合物

    公开(公告)号:US5458890A

    公开(公告)日:1995-10-17

    申请号:US711259

    申请日:1991-06-04

    摘要: Flavored food and pharmaceutical compositions include one or more flavor additives incorporated within polymeric particles, usually within an internal pore network defined by individual polymeric particles. The polymeric particles are, in turn, dispersed within and/or over a surface of an orally-deliverable matrix material, which is usually a solid or semi-solid substrate. In the case of chewable compositions, the flavor additives will be released into the orally-deliverable matrix material as the composition is chewed and held in the mouth, thus prolonging the flavor of the composition. In the case of dried powders and mixes, the flavor will typically be made available as the product is consumed or be released into the matrix material as the composition is further processed. When two flavors are combined with the polymeric particles, the relative amounts of the additives can be selected to provide simultaneous release and exhaustion of the additives.

    摘要翻译: 调味食品和药物组合物包括掺入聚合物颗粒内的一种或多种风味添加剂,通常在由单个聚合物颗粒限定的内部孔网内。 聚合物颗粒又分散在通常为固体或半固体基质的经口输送的基质材料的表面内和/或之上。 在可咀嚼的组合物的情况下,当组合物咀嚼并保持在口中时,风味添加剂将释放到口服递送的基质材料中,从而延长组合物的风味。 在干燥粉末和混合物的情况下,当组合物进一步加工时,通常会将产品消耗或释放到基质材料中,从而获得风味。 当两种口味与聚合物颗粒结合时,可以选择添加剂的相对量以提供添加剂的同时释放和耗尽。

    System and method for transdermal drug delivery
    8.
    发明授权
    System and method for transdermal drug delivery 失效
    用于透皮给药的系统和方法

    公开(公告)号:US5028435A

    公开(公告)日:1991-07-02

    申请号:US355718

    申请日:1989-05-22

    IPC分类号: A61K9/70

    CPC分类号: A61K9/7023

    摘要: Transdermal drug delivery systems comprise a backing or enclosure having a matrix layer which incorporates a drug and a percutaneous enhancer for the drug. The percutaneous enhancer and/or drug will be contained within polymeric particles dispersed through the matrix layer, where the polymeric particles define pore networks which are sized to release the enhancer and/or drug into the matrix layer at rate(s) selected to provide for a desired rate of drug penetration. By isolating the enhancer within the polymeric particles, adverse interactions between the enhancer and the matrix layer and/or the drug can be minimized. Moreover, the release rate of the enhancer into the matrix layer can be carefully controlled, which in turn controls the penetration rate of the drug into the treated host.